Emily Dorman; David Bishai


Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(5):605-613. 

In This Article

Expert commentary

Despite over 80 years of research into male contraception, condoms, vasectomy, withdrawal and abstinence remain the only options for male fertility control. Challenges in physiology, acceptability and safety have been obstacles in male method development, but there is great potential for the current pipeline of products to produce a safe and acceptable novel option that will improve on the efficacy of temporary male methods. Doubts over the market for male contraception persist and may have contributed to the pharmaceutical industry's exit from the field. However, a growing body of evidence indicates that both men and women are strongly interested in using a novel male method. Furthermore, owing to modern paternity testing methods, child support payments are a real and significant financial burden fathers face today. This potential burden is estimated to be US$4800 per year for a man in the USA relying on condoms. Were a novel method with 99% efficacy available, it would reduce this burden to US$4320, making financial sense for a man to spend up to US$4319 per year on a method with 99% efficacy.